Haemophilia is a mostly inherited genetic disorder that impairs the body’s ability to make blood clots, a process needed to stop bleeding. The three forms of hemophilia are hemophilia A, B, and C. Haemophilia isn’t curable, but it can be treated to minimize symptoms and prevent future health complications. The treatment of hemophilia may involve prophylaxis, management of bleeding episodes, treatment of factor VIII (FVIII) inhibitors, and treatment and rehabilitation of hemophilia synovitis. Hemophilia is treated by replacing the protein that is missing in the blood. All products available to treat hemophilia need to be injected directly into the bloodstream. The preferred treatment for hemophilia is factor replacement therapy. Concentrates of clotting factor VIII (for hemophilia A) or clotting factor IX (for hemophilia B) are slowly dripped or injected into a vein. Plasma derived factor concentrates that are made from human blood. Blood contains plasma, which contains proteins, antibodies, albumin and clotting factors, while recombinant factor concentrates are manufactured using hamster cells. Antifibrinolytic medicines (including tranexamic acid and epsilon aminocaproic acid) may be used with replacement therapy. They’re usually given as a pill, and they help keep blood clots from breaking down. Desmopressin (DDAVP) is a man-made hormone used to treat people who have mild hemophilia A. DDAVP isn’t used to treat hemophilia B or severe hemophilia A.
The global hemophilia treatment market segmentation is based on drug type (antifibrinolytic agents, desmopressin, plasma derived coagulation factor concentrates – factor VIII, factor IX, combination, recombinant coagulation factor concentrates – factor VIII, factor IX, combination), indication type (acquired hemophilia, hemophilia a, hemophilia b, hemophilia c), and distribution channel (e-commerce, hospital pharmacies, retail pharmacies).
The global hemophilia treatment market report provides market size (Revenue US$ Million 2014 to 2021), market share, trends and forecasts growth trends (CAGR%, 2017 to 2021). The global hemophilia treatment market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. The global hemophilia treatment market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and also tracks the major competitors operating in the market by company overview, financial snapshot, key products, technologies and services offered, market share analysis and recent trends in the global market.
Major players operating in the global hemophilia treatment market and included in this report are Bayer AG, Biogen, Biotest AG, CSL Behring, F. Hoffmann-La Roche Ltd., Kedrion, Novo Nordisk A/S, Octapharma AG, Pfizer, Inc., and Shire Plc.